FDA Requests Comments on Proposed Collection of Information for Biological Product Reporting

Summary

The Food and Drug Administration (FDA) is seeking public comment on a proposed collection of information related to the reporting of biological product deviations and human cells, tissues, and cellular and tissue-based product deviations in manufacturing, as part of its submission to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.